View Sanofi-Aventis' Q3 Earnings Report
Highlights
- Good performances from Lovenox(R) (+13.7%) and Lantus(R) (+21.7%) across all three geographic regions, continuation of strong uptrend in the presence of Plavix(R) in the United States (+11.3%) and Japan (+50.3%)
- Sales growth of 20.9% in emerging markets
- Strong growth for the Pentacel(R) and Menactra(R) vaccines; substantial proportion of seasonal and A/H1N1 vaccines sales anticipated in the fourth quarter
- OTC sales up 26.3%
- Launch of Multaq(R) in the United States on target; positive opinion from the CHMP in Europe, and approval in Canada and Switzerland
- Impact of competition from generics of Eloxatin(R) in the United States and Plavix(R) in some European countries more than offset by growth drivers
Check out Sanofi-Aventis' current earnings estimates from CNN Money
Sanofi-Aventis' Website: http://www.Sanofi-Aventis.us
Read more on
